NCT06735612Terminated
Respiratory Syncytial Virus Infection In Exacerbations of Chronic Obstructive Pulmonary Diasease: The RECODE Study
Source: ClinicalTrials.gov · Last updated 14 Sept 2026
Reason given: After extending RECODE recruitment for a second year due to low enrolment, the Sponsor closed it on 1 May 2026, after the second RSV season, with 716/892 patients. Further non-RSV recruitment offered limited value; there were no safety concerns.
Brief summary (registry, in English)
The goal of this observational study is to determine the prevalence of respiratory syncytial virus (RSV) infection and evaluate its association with clinical outcomes in patients with chronic obstructive pulmonary disease (COPD) who experience exacerbations during the RSV season (October-April). The main question it aims to answer is: * What is the prevalence of RSV infection in patients with COPD during exacerbations in the RSV season? * Does RSV infection lead to worse clinical outcomes, including hospitalization, longer length of stay, acute cardiovascular events, and/or death in patients with COPD exacerbations? Researchers will compare patients with RSV infection to those without RSV infection to see if RSV infection results in worse clinical outcomes, such as increased hospitalization, longer stays, cardiovascular events, or death. Participants will: * Be adults diagnosed with COPD who present to the emergency department or day hospital due to acute exacerbations of their respiratory symptoms. * Receive treatment as per standard clinical care for COPD exacerbations, including long-acting bronchodilators and inhaled corticosteroids, and may complete a course of antibiotics and/or oral corticosteroids if prescribed during hospitalization. * Undergo diagnostic testing for RSV infection as part of the clinical routine to determine the presence or absence of the virus during their exacerbation. * Have clinical outcomes monitored, including hospitalization rate, length of stay, and any acute cardiovascular events, as well as mortality during the exacerbation period. * Provide relevant demographic and clinical data, including medical history, COPD severity, comorbidities, and previous exacerbation events.
- Status (registry)
- Terminated
- Study type
- Observational
- Enrollment
- 716 (actual)
- First submitted
- 11 Dec 2024
- Start date
- 16 Dec 2024
- Primary completion date
- 1 May 2026
- Lead sponsor
- Fundacio Privada Mon Clinic Barcelona
- Diseases
- COPD
- NCT number
- NCT06735612
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous RSV vaccination (other vaccines will be allowed and recorded)
Other illness
- Active cancer (or any other disease) that may alter the immune status of the patient
- Neurologic disorders that incapacitate the participation of the patient
Other
- No signing of the informed consent
Who the study is looking for
- Female or male
- ≥50 years of age
- Seeking urgent medical attention because of ECOPD, as defined by the Rome consensus definition: "in a patient with COPD, an exacerbation is an event characterized by dyspnea and/or cough and sputum that worsen over <14 d, which may be accompanied by tachypnoea and/or tachycardia and is often associated with increased local and systemic inflammation caused by airway infection, pollution, or other insult to the airways"
Age in the registry: 50 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Clinic de Barcelona | Barcelona | Spain | Unknown status |
Related publications
- Respiratory syncytial virus infection in COPD exacerbations: the RECODE study protocol.BMJ Open · 2026 · PMID 42476737
This page is information, not medical advice. Discuss any trial with your doctor.